Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
New England Journal of Medicine2014Vol. 370(23), pp. 2169–2179
Citations Over TimeTop 1% of 2014 papers
Abstract
Once-weekly intravenous dalbavancin was not inferior to twice-daily intravenous vancomycin followed by oral linezolid for the treatment of acute bacterial skin and skin-structure infection. (Funded by Durata Therapeutics; DISCOVER 1 and DISCOVER 2 ClinicalTrials.gov numbers, NCT01339091 and NCT01431339.).
Related Papers
- → Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices(2021)28 cited
- → Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus(2003)77 cited
- → Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo(2004)57 cited
- → In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains(2016)22 cited
- → Long‐Acting Lipoglycopeptides Can Interfere With Vancomycin Therapeutic Drug Monitoring(2021)4 cited